---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-007179"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:47:29.976261+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Celldex Q3 net loss $67M; barzolvolimab Phase 2 data positive in urticarias

## Summary
- Net loss of $67.0M ($1.01/share) vs $42.1M in Q3 2024; cash use $48.6M in operations.
- Cash & securities $583.2M as of Sep 30, 2025; runway through 2027.
- Phase 2 barzolvolimab met endpoints in CSU, ColdU, and SD; 71% complete response at 52 weeks (CSU).
- Phase 1 CDX-622 (bispecific SCF & TSLP) well tolerated; Part 2 enrollment ongoing.
- Teri Lawver hired as SVP, Chief Commercial Officer; Phase 3 ColdU/SD study to start Dec 2025.

## SEC filing metadata
- accession: 0001171843-25-007179
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000117184325007179/0001171843-25-007179-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000117184325007179/f8k_111025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-007179
- JSON: https://secwatch.observer/filing/0001171843-25-007179.json
- Plain text: https://secwatch.observer/filing/0001171843-25-007179.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.